← back to search

Kristin Goddard

University of North Carolina at Chapel Hill · US
Area of research
Infectious Diseases · Health
Research interest
Research interests include Vaccine Coverage and Hesitancy, SARS-CoV-2 and COVID-19 Research, Influenza Virus Research Studies, and Respiratory viral infections research.
h-index
38
citations
5,544
works
116
NIH funding
primary concept
Medicine
email

Recent publications

In a shifting policy era: California provider knowledge and practice of medical exemption laws during the COVID-19 pandemic.
2026cited by 0position: contributordoi
Risk of Immune Thrombocytopenic Purpura Recurrence Following Second Measles-Containing Vaccine Dose.
2025cited by 1position: contributordoi
Influenza Vaccination During Pregnancy and Infant Influenza in the First 6 Months of Life.
2025cited by 0position: contributordoi
Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus.
2025cited by 0position: contributordoi
Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022-2023.
2025cited by 0position: contributordoi
Religious Service Attendance, COVID-19 Vaccine Attitudes, and COVID-19 Vaccination Status: A Vaccine Safety Datalink Member Survey, 2022-2023.
2025cited by 0position: contributordoi
Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
2025cited by 0position: contributordoi
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
2024cited by 72position: contributordoi
Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
2024cited by 45position: contributordoi
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023.
2024cited by 23position: contributordoi
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023.
2024cited by 19position: contributordoi
Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network.
2024cited by 16position: contributordoi
Overview of U.S. COVID-19 vaccine safety surveillance systems.
2024cited by 15position: contributordoi
Attitudes Toward COVID-19 Vaccines Among Pregnant and Recently Pregnant Individuals.
2024cited by 11position: contributordoi
Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study.
2024cited by 8position: contributordoi
Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children.
2024cited by 3position: contributordoi
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
2023cited by 71position: contributordoi
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
2023cited by 43position: contributordoi
Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life.
2023cited by 41position: contributordoi
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023.
2023cited by 37position: contributordoi
Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.
2023cited by 15position: contributordoi
Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
2023cited by 15position: contributordoi
Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.
2023cited by 15position: contributordoi
Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network.
2023cited by 15position: contributordoi
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.
2023cited by 12position: contributordoi
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
Vaccine 2023cited by 11position: contributordoi
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
Vaccine 2023cited by 9position: contributordoi
Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant.
2023cited by 8position: contributordoi
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
2023cited by 8position: contributordoi
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021
Vaccine 2023cited by 8position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Stephanie A. Irving · Vanderbilt University Medical Center28 papers (2019–2025)Manjusha Gaglani · Texas Children's Hospital15 papers (2021–2024)Kempapura Murthy · Baylor Scott & White Health14 papers (2021–2024)Nicola P. Klein · Kaiser Permanente12 papers (2020–2024)Brian E. Dixon · Vanderbilt University Medical Center11 papers (2021–2024) · 10 papers (2020–2024)Ousseny Zerbo · National Institute of Allergy and Infectious Diseases9 papers (2022–2024)Eric Weintraub · Centers for Disease Control and Prevention5 papers (2022–2023) · 4 papers (2023–2024) · 4 papers (2023–2024)Mark W. Tenforde · Centers for Disease Control and Prevention4 papers (2023–2024)Matthew E. Oster · Centers for Disease Control and Prevention4 papers (2022–2024)Karthik Natarajan · NewYork–Presbyterian Hospital4 papers (2023–2024)John Hansen · Kaiser Permanente3 papers (2020–2024) · 3 papers (2022–2025) · 3 papers (2022–2023)Allison L. Naleway · Vanderbilt University Medical Center3 papers (2022–2024)Ned Lewis · Kaiser Permanente2 papers (2022–2022) · 2 papers (2023–2023) · 2 papers (2024–2024)